PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC

June 4-8, 2021; Online at https://conferences.asco.org/am
Longer-term results from PACIFIC show sustained OS and PFS benefit—with 5-year OS and PFS rates of 42.9% and 33.1%, respectively—with concurrent CRT followed by 1 year of durvalumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 478 KB
Released: June 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

On-demand webcast on biomarker-driven care for patients with NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Downloadable slides for oncologists, pharmacists, and nurses: Immunotherapy and chemotherapy for extensive-stage SCLC from Clinical Care Options (CCO)

Released: May 11, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Downloadable summary slideset of key takeaways from a live symposium for nurses on management of EGFR ex20ins+ advanced NSCLC, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Matthew Gubens, MD, MS Released: May 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings